Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Silke Walleser,1 Joshua Ray,2 Helge Bischoff,3 Alain Vergnenègre,4 Hubertus Rosery,5 Christos Chouaid,6 David Heigener,7 Javier de Castro Carpeño,8 Marcello Tiseo,9 Stefan Walzer21Health Economic Consultancy, Renens, Switzerland; 2F Hoffmann-La Roche Pharmaceuticals AG,...

Full description

Bibliographic Details
Main Authors: Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S
Format: Article
Language:English
Published: Dove Medical Press 2012-09-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/maintenance-erlotinib-in-advanced-nonsmall-cell-lung-cancer-cost-effec-a10993

Internet

http://www.dovepress.com/maintenance-erlotinib-in-advanced-nonsmall-cell-lung-cancer-cost-effec-a10993

Similar Items